Loading...
•
Sep 30, 2021
Ocular Therapeutix Q3 2021 Earnings Report
Ocular Therapeutix reported third quarter financial results and business update.
Key Takeaways
Ocular Therapeutix reported a net product revenue of DEXTENZA® for the quarter was $11.9 million, a 120% increase over the third quarter of 2020. The company reported net income of $2.7 million, or income of $0.03 per share on a basic basis and a loss of $(0.23) per share on a diluted basis for the three months ended September 30, 2021.
DEXTENZA® recorded net quarterly sales of $11.9 million, representing year-over-year growth of 120%.
FDA approved sNDA for DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis.
DEXTENZA will be paid through the end of 2022 and is eligible for separate payment in the ambulatory surgery center beyond 2022.
Phase 2 clinical trial topline results for OTX-DED, clinical trial in episodic dry eye disease expected in the first quarter of 2022.
Ocular Therapeutix
Ocular Therapeutix
Ocular Therapeutix Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.com Forward Guidance
The Company believes that existing cash and cash equivalents, as of September 30, 2021, will enable the Company to fund planned operating expenses, debt service obligations and capital expenditure requirements through 2023.